Neoadjuvant therapy protocol and liver transplantation in combination with pancreatoduodenectomy for the treatment of hilar cholangiocarcinoma occurring in a case of primary sclerosing cholangitis: case report with a more than 8-year disease-free survival

Transplant Proc. 2011 May;43(4):1187-9. doi: 10.1016/j.transproceed.2011.01.140.

Abstract

Cholangiocarcinoma has historically represented a major contraindication to liver transplantation at many centers because of its high recurrence rate and low disease-free survival rate, even after radical surgery. Novel neoadjuvant therapy protocols combined with demolitive surgery and liver transplantation seem to achieve successful results in terms of overall and disease-free survivals. Surgery frequently seems to be unsatisfactory only for patients also suffering from chronic cirrhosis or end-stage liver disease. We have reported a case of hilar cholangiocarcinoma occurring in a case of primary sclerosing cholangitis treated with neoadjuvant radiochemotherapy and endoscopic brachytherapy, followed by liver transplantation combined with pancreatoduodenectomy, who has survived free of disease for >8 years.

Publication types

  • Case Reports

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use
  • Bile Duct Neoplasms / etiology
  • Bile Duct Neoplasms / pathology
  • Bile Duct Neoplasms / surgery*
  • Bile Ducts, Intrahepatic / pathology
  • Bile Ducts, Intrahepatic / surgery*
  • Brachytherapy
  • Chemotherapy, Adjuvant
  • Cholangiocarcinoma / etiology
  • Cholangiocarcinoma / pathology
  • Cholangiocarcinoma / surgery*
  • Cholangitis, Sclerosing / complications*
  • Disease-Free Survival
  • Female
  • Fluorouracil / therapeutic use
  • Hepatectomy
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Liver Transplantation*
  • Middle Aged
  • Neoadjuvant Therapy
  • Pancreaticoduodenectomy*
  • Radiotherapy, Adjuvant
  • Tacrolimus / therapeutic use
  • Time Factors
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • Immunosuppressive Agents
  • Fluorouracil
  • Tacrolimus